Antiepileptogenesis in humans: Disappointing clinical evidence and ways to move forward

Current Opinion in Neurology

Volumn 27, Issue 2, 2014, Pages 227-235

  Trinka, Eugen ^a,b   Brigo, Francesco ^c,d  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF SALZBURG   (Austria)

^c UNIVERSITY OF VERONA   (Italy)

^d FRANZ TAPPEINER HOSPITAL   (Italy)

Author keywords

antiseizure drugs; biomarker; drug trial; epileptogenesis; seizure prevention

Indexed keywords

EVEROLIMUS; RAPAMYCIN; VALPROIC ACID;

CHEMORADIOTHERAPY; COMORBIDITY; EPILEPSY; EPILEPTOGENESIS; GLIOBLASTOMA; HUMAN; REVIEW; SURVIVAL; TUBEROUS SCLEROSIS;

ANIMALS; ANTICONVULSANTS; BRAIN DISEASES; EPILEPSY; HUMANS;

EID: 84896399969     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000067     Document Type: Review

References (72)

1. Galanopoulou AS, Simonato M, French JA, O'Brien TJ. Joint AES/ILAE translational workshop to optimize preclinical epilepsy research. Epilepsia 2013; 54 (Suppl 4):1-2.
2. Galanopoulou AS, Buckmaster PS, Staley KJ, et al. Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia 2012; 53: 571-582.
3. French JA, White HS, Klitgaard H, et al. Development of new treatment approaches for epilepsy: unmet needs and opportunities. Epilepsia 2013; 54 (Suppl 4):3-12.
4. Galanopoulou AS, Kokaia M, Loeb JA, et al. Epilepsy therapy development: technical and methodologic issues in studies with animal models. Epilepsia 2013; 54 (Suppl 4):13-23.
5. Wilcox KS, Dixon-Salazar T, Sills GJ, et al. Issues related to development of new antiseizure treatments. Epilepsia 2013; 54 (Suppl 4):24-34.
6. Pitkänen A, Nehlig A, Brooks-Kayal AR, et al. Issues related to development of antiepileptogenic therapies. Epilepsia 2013; 54 (Suppl 4):35-43.
7. Brooks-Kayal AR, Bath KG, Berg AT, et al. Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy. Epilepsia 2013; 54 (Suppl 4):44-60.
8. Engel J Jr, Pitkänen A, Loeb JA, et al. Epilepsy biomarkers. Epilepsia 2013; 54 (Suppl 4):61-69.
9. O'Brien TJ, Ben-Menachem E, Bertram EH 3rd, et al. Proposal for a 'phase II' multicenter trial model for preclinical new antiepilepsy therapy development. Epilepsia 2013; 54 (Suppl 4):70-74.
10. Simonato M, French JA, Galanopoulou AS, O'Brien TJ. Issues for new antiepilepsy drug development. Curr Opin Neurol 2013; 26:195-200.
11. Pitkänen A. Therapeutic approaches to epileptogenesis: hope on the horizon. Epilepsia 2010; 51 (Suppl 3):2-17.
12. Pitkänen A, Lukasiuk K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol 2011; 10:173-186.
13. Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepilep-tic drugs: meta-analysis of controlled trials. Epilepsia 2001; 42:515-524.
14. Adelöw C, Andell E, Amark P, et al. Newly diagnosed single unprovoked seizures and epilepsy in Stockholm, Sweden: first report from the Stockholm Incidence Registry of Epilepsy (SIRE). Epilepsia 2009; 50:1094-1101.
15. Dichter MA. Emerging concepts in the pathogenesis of epilepsy and pilepto-genesis. Arch Neurol 2009; 66:443-447.
16. Schmidt D. Is antiepileptogenesis a realistic goal in clinical trials? Concerns and new horizons. Epileptic Disord 2012; 14:105-113.
17. Sloviter RS. Hippocampal epileptogenesis in animal models of mesial temporal lobe epilepsy with hippocampal sclerosis: the importance of the 'latent period' and other concepts. Epilepsia 2008; 49 (Suppl 9):85-92.
18. Sloviter RS, Bumanglag AV. Defining 'epileptogenesis' and identifying 'anti-epileptogenic targets' in animal models of acquired temporal lobe epilepsy is not as simple as it might seem. Neuropharmacology 2013; 69:3-15.
19. Temkin NR. Preventing and treating posttraumatic seizures: the human experience. Epilepsia 2009; 50 (Suppl 2):10-13.
20. Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010; 362:790-799.
21. Blumenfeld H, Klein JP, Schridde U, et al. Early treatment suppresses the development of spike-wave epilepsy in a rat model. Epilepsia 2008; 49:400-409.
22. Russo E, Citraro R, Scicchitano F, et al. Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy. Epilepsia 2010; 51:1560-1569.
23. Russo E, Citraro R, Scicchitano F, et al. Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model. Epilepsia 2011; 52: 1341-1350.
24. van Luijtelaar G, Mishra AM, Edelbroek P, et al. Antiepileptogenesis: electro-physiology, diffusion tensor imaging and behavior in a genetic absence model. Neurobiol Dis 2013; 60:126-138.
25. Dezsi G, Ozturk E, Stanic D, et al. Ethosuximide reduces epileptogenesis and behavioral comorbidity in the GAERS model of genetic generalized epilepsy. Epilepsia 2013; 54:635-643.
26. Neligan A, Haliasos N, Pettorini B, et al. A survey of adult and pediatric epilepsy surgery in the United Kingdom. Epilepsia 2013; 54:e62-e65.
27. Van Gompel JJ, Ottman R, Worrell GA, et al. Use of anterior temporal lobectomy for epilepsy in a community-based population. Arch Neurol 2012; 69:1476-1481.
28. Englot DJ, Ouyang D, Garcia PA, et al. Epilepsy surgery trends in the United States, 1990-2008. Neurology 2012; 78:1200-1206.
29. Helmstaedter C, May TW, von Lehe M, et al. Temporal lobe surgery in Germany from 1988 to 2008: diverse trends in etiological subgroups. Eur J Neurol 2013. [Epub ahead of print]
30. Beghi E. Overview of studies to prevent posttraumatic epilepsy. Epilepsia 2003; 44 (Suppl 10):21-26.
31. Schierhout G, Roberts I. Antiepileptic drugs for preventing seizures following acute traumatic brain injury. Cochrane Database Syst Rev 2001; 4:CD000173.
32. Jennett WB, Lewin W. Traumatic epilepsy after closed head injuries. J Neurol Neurosurg Psychiatry 1960; 23:295-301.
33. Jennett WB. Early traumatic epilepsy. Definition and identity. Lancet 1969; 1:1023-1025.
34. Chang BS, Lowenstein DH. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003; 60:10-16.
35. Inaba K, Menaker J, Branco BC, et al. A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis. J Trauma Acute Care Surg 2013; 74:766-771.
36. Cotton BA, Kao LS, Kozar R, Holcomb JB. Cost-utility analysis of levetirace-tam and phenytoin for posttraumatic seizure prophylaxis. J Trauma 2011; 71:375-379.
37. Glötzner FL, Haubitz I, Miltner F, et al. Seizure prevention using carbamaze-pine following severe brain injuries. Neurochirurgia (Stuttg) 1983; 26:66-79.
38. McQueen JK, Blackwood DH, Harris P, et al. Low risk of late posttraumatic seizures following severe head injury: implications for clinical trials of prophylaxis. J Neurol Neurosurg Psychiatry 1983; 46:899-904.
39. Young B, Rapp RP, Norton JA, et al. Failure of prophylactically administered phenytoin to prevent late posttraumatic seizures. J Neurosurg 1983; 58:236-241.
40. Young B, Rapp RP, Norton JA, et al. Failure of prophylactically administered phenytoin to prevent early posttraumatic seizures. J Neurosurg 1983; 58:231-235.
41. Young B, Rapp RP, Norton JA, et al. Failure of prophylactically administered phenytoin to prevent posttraumatic seizures in children. Childs Brain 1983; 10:185-192.
42. Pechadre JC, Lauxerois M, Colnet G, et al. Prevention of late posttraumatic epilepsy by phenytoin in severe brain injuries. 2 years' follow-up. Presse Med 1991; 20:841-845.
43. Temkin NR, Dikmen SS, Wilensky AJ, et al. A randomized, double-blind study of phenytoin for the prevention of posttraumatic seizures. N Engl J Med 1990; 323:497-502.
44. Dikmen SS, Temkin NR, Miller B, et al. Neurobehavioral effects of phenytoin prophylaxis of posttraumatic seizures. JAMA 1991; 265:1271-1277.
45. Manaka S. Cooperative prospective study on posttraumatic epilepsy: risk factors and the effect of prophylactic anticonvulsant. Jpn J Psychiatry Neurol 1992; 46:311-315.
46. Okuda S, Takano S, Ueno M, et al. Clinical features of late-onset poststroke seizures. J Stroke Cerebrovasc Dis 2012; 21:583-586.
47. Kwan J, Wood E. Antiepileptic drugs for the primary and secondary prevention of seizures after stroke. Cochrane Database Syst Rev 2010; 6:CD005398.
48. Marigold R, Günther A, Tiwari D, Kwan J. Antiepileptic drugs for the primary and secondary prevention of seizures after subarachnoid haemorrhage. Cochrane Database Syst Rev 2013; 6:CD008710.
49. van Tuijl JH, van Raak EP, de Krom MC, et al. Early treatment after stroke for the prevention of late epileptic seizures: a report on the problems performing a randomised placebo-controlled double-blind trial aimed at antiepileptogen-esis. Seizure 2011; 20:285-291.
50. Vecht CJ, van Breemen M. Optimizing therapy of seizures in patients with brain tumors. Neurology 2006; 67 (Suppl 4):10-13.
51. Delattre J, Safai B, Posner JB. Erythema multiforme and Stevens-Johnson syndrome in patients receiving cranial irradiation and phenytoin. Neurology 1988; 38:194-198.
52. Vecht CJ, Wagner GL, Wilms EB. Treating seizures in patients with brain tumors: drug interactions between antiepileptic and chemotherapeutic agents. Semin Oncol 2003; 30 (Suppl 19):49-52.
53. Tremont-Lukats IW, Ratilal BO, Armstrong T, Gilbert MR. Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev 2008; 2:CD004424.
54. North JB, Penhall RK, Hanieh A, et al. Phenytoin and postoperative epilepsy. A double-blind study. J Neurosurg 1983; 58:672-677.
55. Lee ST, Lui TN, Chang CN, et al. Prophylactic anticonvulsants for prevention of immediate and early postcraniotomy seizures. Surg Neurol 1989; 31:361-364.
56. Franceschetti S, Binelli S, Casazza M, et al. Influence of surgery and anti-epileptic drugs on seizures symptomatic of cerebral tumours. Acta Neurochir (Wien) 1990; 103:47-51.
57. Glantz MJ, Cole BF, Friedberg MH, et al. A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 1996; 46:985-991.
58. Forsyth PA, Weaver S, Fulton D, et al. Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci 2003; 30:106-112.
59. Weller M, Gorlia T, Cairncross JG, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 2011; 77:1156-1164.
60. Barker CA, Bishop AJ, Chang M, et al. Valproic acid use during radiation therapy for glioblastoma associated with improved survival. Int J Radiat Oncol Biol Phys 2013; 86:504-509.
61. Kerkhof M, Dielemans JC, van Breemen MS, et al. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro Oncol 2013; 15:961-967.
62. Tsai HC, Wei KC, Tsai CN, et al. Effect of valproic acid on the outcome of glioblastoma multiforme. Br J Neurosurg 2012; 26:347-354.
63. Löscher W, Brandt C. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol Rev 2010; 62:668-700.
64. Ryther RC, Wong M. Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy. Curr Neurol Neurosci Rep 2012; 12:410-418.
65. Cohen I, Navarro V, Clemenceau S, et al. On the origin of interictal activity in human temporal lobe epilepsy in vitro. Science 2002; 298:1418-1421.
66. Dzhala VI, Talos DM, Sdrulla DA, et al. NKCC1 transporter facilitates seizures in the developing brain. Nat Med 2005; 11:1205-1213.
67. Koyama R, Tao K, Sasaki T, et al. GABAergic excitation after febrile seizures induces ectopic granule cells and adult epilepsy. Nat Med 2012; 18:1271-1278.
68. Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nat Rev Neurol 2011; 7:31-40.
69. Vezzani A, Bartfai T, Bianchi M, et al. Therapeutic potential of new antiin-flammatory drugs. Epilepsia 2011; 52 (Suppl 8):67-69.
70. Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res 2013; 103:2-30.
71. Mani R, Pollard J, Dichter MA. Human clinical trials in antiepileptogenesis. Neurosci Lett 2011; 497:251-256.
72. Löscher W, Klitgaard H, Twyman RE, Schmidt D.New avenues for antiepileptic drug discovery and development. Nat Rev Drug Discov 2013; 12:757-776.